Subjects on felbamate with less than 18 months exposure.

Subjects on vigabatrin, whose visual field has not been assessed as per recommendation of the manufacturer, i.e. every 6 months.

Presence of known pseudoseizures within the last year.

Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors.

Uncountable seizures (clusters) or history of convulsive status epilepticus within the last five years.

Open Label Safety and Efficacy Study of Levetiracetam in Korean Patients With Epilepsy